New diabetic drug liraglutide for the treatment of diabetes and weight reduction is approved in Europe. European commission granted marketing authorisation of victoza. This new drug is developed by Novo Nordisk for the treatment of Type 2 diabetes. Liraglutide the trade name of which is Victoza works by stimulating the release of insulin only when glucose levels become too high and by inhibiting appetite. Liraglutide is a human analog of Glucagon like Peptide-1 (GLP-1). It stimulates glucose-dependent insulin secretion, decreases glucagons secretion, slows gastric motility and emptying, and reduces appetite, the investigators said. Liraglutide also has a beneficial impact on systolic blood pressure, a key cardiovascular risk factor in type 2 diabetes


Read more:
http://www.drugs.com/news/novo-nordisk-s-victoza-liraglutide-receives-marketing-authorisation-europe-3-july-2009-18653.html
http://diabetes.webmd.com/news/20090608/victoza-for-diabetes-better-than-byetta